Pierluigi Paracchi’s Post

Join this webinar to explore how incorporating biomarker strategies and NGS and AI approaches, at the early stages of preclinical research can enhance the drug discovery and development process. These are key components of modern personalized medicine strategies providing many benefits for early cancer detection, recruitment, and stratifications of patients into subgroups, treatment selection, minimal residual disease surveillance and monitoring. #AI #Biomarkers #PersonalizedMedicine

✨ The Power of NAi - De-risking Clinical Trials ✨ Using multiomic data from tissue, blood, and urine samples collected from patients in a Phase I trial, NAi can help trial sponsors map patient biology and better understand the mechanism of action and safety—not just for the population as a whole, but also how the drug interacts with patients with specific germline or somatic genomic profiles. NAi increases the predictability of clinical trial outcomes. With NAi, BPGbio, Inc. has run three successful trials in oncology and two in rare disease. To read more of the story about NAi de-risking clinical trials please visit: https://lnkd.in/gyc49x8e BPGbio, Inc. presents a series of short stories on how our NAi Interrogative Biology Platform is being used to make drug discovery faster and more reliable. One more coming this week! #cancer #Research #Innovation #Biotechnology #Multiomics #SpatialOmics #AI #DrugDiscovery #NAiInterrogativeBiology #clinicaltrial #biomarker

Join this webinar to explore how incorporating biomarker strategies and NGS and AI approaches, at the early stages of preclinical research can enhance the drug discovery and development process. These are key components of modern personalized medicine strategies providing many benefits for early cancer detection, recruitment, and stratifications of patients into subgroups, treatment selection, minimal residual disease surveillance and monitoring. #AI #Biomarkers #PersonalizedMedicine

View the featured discussions of our recent live webinar focusing on the importance of broad molecular profiling to avoid missing detection of actionable biomarkers, and how to use new targeted treatment options to optimize care of patients in advanced NSCLC with METex14 skipping mutations. https://lnkd.in/eKZTMb3v

Great overview summarizing current and emerging clinical & translational data in support of neoadjuvant immunotherapy in patients with resectable dMMR & pMMR CRC. https://lnkd.in/eCMhvq-G

#Nucleicacids received a major boost through the ‘proof of concept’ delivered by the tremendously successful COVID-19 #mRNAvaccines. Novel therapeutic applications in major disease areas, including #oncology, continue to show promise in preclinical and early clinical studies, yet challenges remain. Recently published content covering innovative research in this space includes: • A panel of #mRNA thought-leaders providing insights into the ever-expanding reach of mRNA technology, exploring how and where it will impact the advanced therapies space moving forward https://buff.ly/3XsldHi • An article highlighting the key R&D directions for mRNA and associated technologies, as they expand beyond #prophylacticvaccines https://buff.ly/3RASU5O • A poster that shares the advice of sector thought-leaders on key challenges facing the #mRNAtherapeutics field. https://buff.ly/3RASU5O These are just three of the resources available on our Purification Hub. The hub explores the key role that #viralvectors and mRNA play in cell and #genetherapy, the current challenges facing the field, and potential solutions for successful manufacture. Once you’ve read your first piece of content, all the rest is available to you open access. Visit the hub below: https://buff.ly/3T12nDj

We need to change the paradigm in LA-HNSCC. Adding anti-PD1/PDL1 concurrently or adjuvantly has not worked. I think the solution will come with better biomarkers, changing radiation dosing, and rationally applied therapy sequencing. https://lnkd.in/g4ykccrp

Better biomarkers and personalized approach should be adopted

NSCLC Mechanisms of resistance to targeted therapy “EGFR C797X (C797S or C797G) can develop different allelic contexts with T790M. Currently defined allelic contexts of EGFR C797X relative to T790M include configurations either in cis (on the same allele) or in trans (on different alleles). The specific allelic context of EGFR C797X has been associated with the effectiveness of subsequent treatments. However, most of the supporting evidence comes from preclinical studies and isolated case reports.7, 8, 9, 10, 11 Moreover, evidence is scant regarding the frequency and clinical outcomes of patients harboring different allelic contexts of C797X. In this multicenter collaboration, we characterized the heterogeneity among EGFR C797X–mutant advanced NSCLC on the basis of the allelic context of C797X. In addition to clinicopathologic features, the subtypes exhibited marked differences in mutational landscape, responses to the first subsequent therapy, and clinical outcomes.” #NSCLC #resistance #EGFR #targetedtherapy #alleliccontext #cis #trans

We look forward to introducing the PredicineCARE™ Ultra NGS data poster presentation in collaboration with Dana Farber Cancer Institute and Harvard Medical School on Day 1 of ASCO GI! Development and application of an ultra-sensitive ctDNA mutation profiling assay in monitoring therapy response and drug resistance    The highlights of this poster presentation include:    • Predicine has developed an ultra-sensitive NGS assay, PredicineCARE™ Ultra cfDNA Assay, to detect the low-frequency ctDNA mutants for monitoring therapy response and drug resistance. • PredicineCARE™ Ultra cfDNA Assay exhibited exceptional sensitivity (98.0% detection rate at a LoD down to 0.075% MAF) and high levels of specificity, precision and accuracy. • The addition of ~30% new low-frequency ctDNA mutants was detected compared to the standard ctDNA mutant profiling assay in a clinical trial for monitoring therapy response and drug resistance, indicating superior performance of the PredicineCARE™ Ultra cfDNA Assay in clinical applications.    Come and visit Booth #24 and discover our unique liquid biopsy solutions in support of global clinical trials, CDx development and commercialization. Schedule a meeting with the Predicine team:  https://lnkd.in/g8JK7vuc    Learn more about PredicineCARE™ Ultra and our other assays: https://lnkd.in/gS_-5H6f    #ASCOGI24 #precisiononcology #diagnostics #NGS #liquidbiopsy #mrd #ctdna #clinicaltrials